Department of Medicine, Division of Hematology/Oncology
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibition. In addition, the TKI resistance of LSCs is not associated with the BCR-ABL kinase domain mutations. These observations indicate that TKI-insensitive LSCs and TKI-sensitive leukemic progenitor cells are biologically different, which leads us to believe that LSCs and more differentiated leukemic cells have different genetic mechanisms. Further study of LSCs to identify the novel gene signatures and mechanisms that control the function and molecular phenotype of LSCs is critical. In this mini-review, we will discuss our current understanding of the biology of LSCs and novel genes that could serve as a molecular signature of LSCs in CML. These novel genes could also serve as potential targets for eradicating LSCs in CML.
Rights and Permissions
Citation: Chen Y, Li S. Molecular signatures of chronic myeloid leukemia stem cells. Biomark Res. 2013 Jun 6;1(1):21. doi: 10.1186/2050-7771-1-21. Link to article on publisher's site
BCR-ABL, Leukemic stem cells, CML, Biomarker, Hematopoietic stem cells, Cancer stem cells
Chen, Yaoyu and Li, Shaoguang, "Molecular signatures of chronic myeloid leukemia stem cells" (2013). University of Massachusetts Medical School Faculty Publications. 310.